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Vivisection (BUAV), London, UK
Summary — Assertions that the use of chimpanzees to investigate human diseases is valid scientifically are
frequently based on a reported 98–99% genetic similarity between the species. Critical analyses of the relevance of chimpanzee studies to human biology, however, indicate that this genetic similarity does not
result in sufficient physiological similarity for the chimpanzee to constitute a good model for research, and
furthermore, that chimpanzee data do not translate well to progress in clinical practice for humans.
Leading examples include the minimal citations of chimpanzee research that is relevant to human medicine, the highly different pathology of HIV/AIDS and hepatitis C virus infection in the two species, the lack
of correlation in the efficacy of vaccines and treatments between chimpanzees and humans, and the fact
that chimpanzees are not useful for research on human cancer. The major molecular differences underlying these inter-species phenotypic disparities have been revealed by comparative genomics and molecular
biology — there are key differences in all aspects of gene expression and protein function, from chromosome and chromatin structure to post-translational modification. The collective effects of these differences
are striking, extensive and widespread, and they show that the superficial similarity between human and
chimpanzee genetic sequences is of little consequence for biomedical research. The extrapolation of biomedical data from the chimpanzee to the human is therefore highly unreliable, and the use of the chimpanzee must be considered of little value, particularly given the breadth and potential of alternative
methods of enquiry that are currently available to science.
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Introduction
The validity of using chimpanzees (Pan
troglodytes) in research to investigate the diseases
that affect humans is frequently based on the
reported genetic similarity of the two species. It is
often noted that chimpanzees are 98–99% genetically identical to humans — a figure that was initially derived 40 years ago (1, 2) and was confirmed
more recently by using superior technologies (3).
Advocates of experimentation with chimpanzees
claim it is axiomatic that this genetic similarity
leads to equivalent biological and physiological
similarity, and that because chimpanzees are the
closest relatives of humans, they must constitute a
good — indeed the best — animal species to use for
the study of human disease (4). Thus, the use of
chimpanzees in biomedical research is justified by
its proponents, alongside claims of the crucial role
played by such research in fighting many grave
human diseases.
However, this justification has become increasingly controversial. Given the cognitive and emotional capacities of chimpanzees, and the harmful
consequences of laboratory life and invasive

research for the animals involved (5, 6), profound
ethical considerations have always been the foundation for strong opposition to chimpanzee
research (7, 8). In addition, in recent years a burgeoning scientific case has been made against the
use of chimpanzees in research, which seriously
questions the usefulness and human relevance of
chimpanzee data (9–13; and see http://www.
releasechimps.org/pdfs/chimp-efficacy-paper-main.
pdf and http://www.releasechimps.org/pdfs/ChimpCA-suppl.pdf). Furthermore, it is apparent that
the claimed 98–99% genetic similarity between
humans and chimpanzees is superficial and deceptive. The overall similarity, when all relevant factors are taken into account, is likely to be nearer to
95% (14, 15), or even approaching 93% (16, 17). As
elaborated in this paper, important differences at
all levels of gene expression and protein function,
from chromosome structure to post-translational
modification, combine to generate significant and
widespread biological and physiological differences.
In recent years, such concerns have led to legislation that bans, or at least very severely restricts,
chimpanzee experimentation in the relatively few
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countries where it was ever practised (see http://
www.releasechimps.org/mission/end-chimpanzeeresearch/country-bans/). The exception is the USA,
where approximately 1,000 chimpanzees remain in
laboratories (see http://www.releasechimps.org/
mission/end-chimpanzee-research/), many of them
the last survivors of an intensive breeding programme for HIV/AIDS research that began in 1986
(18). The ethical and scientific concerns that have
been raised have been reflected in substantial public opposition to chimpanzee experimentation (see
http://www.releasechimps.org/mission/endchimpanzee-research/public-opinion/), which has
translated into some degree of legal protection: the
passage of the Chimpanzee Health, Improvement,
Maintenance and Protection (CHIMP) Act in 2000
(19, 20), and the more-recent legislative efforts in
both the US House of Representatives and the US
Senate in the form of the Great Ape Protection Act
(GAPA) in 2009 (21, 22), which was reintroduced
in 2011 as the Great Ape Protection and Cost
Savings Act (GAPCSA; H.R.1513/S.810; 23, 24).
This act would end invasive experimentation on
captive chimpanzees in the USA, bringing the
country into line with the rest of the world, and
would facilitate the retirement of all federally
owned chimpanzees into permanent sanctuaries.
The aim of the present review is to aid the
debate and discussion surrounding the use of
chimpanzees in US laboratories, by examining
the ‘genetic similarity’ argument in the light of
current knowledge regarding the comparative
molecular biology of humans and chimpanzees
and their inter-species differences. Salient information from recent years, along with a consideration of the performance and human relevance of
the chimpanzee model, is synthesised, in order to
illuminate and critically evaluate this argument.

Methods
Papers describing important genetic differences
between humans and chimpanzees, which have
significant or potentially significant functional
biological consequences, were located via the
GoPubMed database (25). Other salient reports
were located in two exceptional reviews of
human/chimpanzee comparative genomics that
were published in 2001 (26) and 2006 (27). A total
of 178 papers, dating from the past decade
(2001–2010), were examined to form the basis of
a review, the aim of which is to illustrate, with a
sound and comprehensive basis, that there are
crucial inter-species differences with extensive
and far-reaching effects. These differences permeate all aspects of gene expression and protein
function, from chromosome and chromatin structure all the way through to post-translational
modification.
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Results
Cytogenetic differences: Fusions, inversions
and translocations
There are numerous well-known structural differences between the human and chimpanzee
genomes. For example, human chromosome 2
results from a fusion of ancestral chromosomes corresponding to chimpanzee chromosomes 12 and 13
(28). Compared to chimpanzees, human chromosomes 1 and 18, as well as others, contain large
inverted stretches, and many human chromosomes
contain large translocated or rearranged segments
(26). These rearrangements exert a significant
influence on the expression of the affected genes
via the ‘position effect’, which results from an
alteration in the location of a gene. The relocation
of a gene can influence its expression via changes
in the proximity and/or nature of cis-acting promoters and enhancers. Furthermore, the local
structural environment of chromatin can alter the
accessibility of transcriptional proteins, and can
exert gene-silencing effects via the influence of
nearby heterochromatic DNA (29). One study
‘conservatively estimated’ that 18% of genes —
numbering some 3,200 — have genomic neighbourhoods that differ between humans and chimpanzees, and may therefore be subject to gene
expression changes due to position effects (30).
Another major difference is found between the Y
chromosomes of humans and chimpanzees. The
male-specific region (MSY) of each of these chromosomes has evolved rapidly over the past six million years, and as a result, the chromosomes now
‘differ radically in sequence, structure and gene
content’ (31). The chimpanzee MSY contains twice
as many massive palindromes as its human counterpart and has lost genes, while the human MSY
has gained genes. X-degenerate regions of the
chimpanzee Y chromosome have lost four out of 16
genes, due to inactivating mutations. In total, the
chimpanzee MSY contains only two-thirds of the
number of genes/gene families in the human MSY,
and just 50% of the protein-coding transcription
units (31).
Mobile DNA elements and copy number
variation
The position effect can also be invoked by the
action of ‘mobile elements’ or ‘transposable elements’ in the genome — sections of DNA that can
move or ‘transpose’ themselves to other genomic
locations. One subclass of these elements can be
classified as long interspersed nuclear elements
(LINEs) and short interspersed nuclear elements
(SINEs; 26); these vary between humans and
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chimpanzees and cause variations in gene expression between them. Mobile elements comprise
almost half of the entire human genome (26, 32),
and significantly affect gene function by physically
disrupting genes, by generating alternative sites
for the splicing of RNA molecules during gene
transcription, or by interfering with gene promoter
and enhancer regions (33). Among other things,
they are responsible for an as yet undefined proportion of large duplicated regions of DNA called
segmental duplications, which in total comprise a
significant 5% of the human genome. While
approximately two-thirds of these duplications are
common to humans and chimpanzees, one-third
are species-specific and have contributed greatly to
the biological differences between humans and
chimpanzees (34).
These duplications, in a phenomenon known as
copy number variation, are responsible for significant disparities in gene expression and subsequent
biological consequences, such as susceptibility to
disease (35). They are known to be one of the most
significant causes of genetic variation among primates (36), and are at the root of many aspects of
intra-species and inter-species diversity, differentially affecting many human and chimpanzee
genes involved in critical processes, such as
immune and inflammatory responses, cell proliferation and tumour formation (37). Clearly, copy
number variation greatly affects the appropriateness of chimpanzee use in the study of human diseases.
In 2006, Bailey and Eichler reported that over 76
million base pairs of DNA are differentially duplicated between chimpanzees and humans (35).
More recently, Armengol and co-workers examined
over 16,000 genes and identified 23 human-specific
copy number differences (CNDs) versus chimpanzees, and 26 chimpanzee-specific CNDs versus
humans, with some of the affected genes having
neuronal functions (36). An earlier analysis
revealed 177 complete and partial gene duplications in humans, but not in chimpanzees; the opposite was true for another 94 genes (34). Half of the
271 genes showed differences in expression — in
fact, genes in duplicated regions are often up to 10
times more likely to show differences in expression
levels than those in other regions (35). It is
axiomatic that many genes with important functions would be affected: the multi-organ cancer
susceptibility gene CHEK2, for example, is present
in nine copies in chimpanzees, but there are 13–16
copies in a typical human genome (38).
Inversions of genetic material are also highly
prevalent, and are different, in the human and
chimpanzee genomes. They are important because
of their effects on gene expression in the vicinity of
the DNA breakpoints where they occur, as well as
their direct interruption of some genes. Such inversions are considered to have been major drivers in
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the speciation process of humans and chimpanzees, and to have contributed greatly to genetic
variation between the two species (33). A significant proportion of these inversions, as well as of
other chromosomal rearrangements, such as the
segmental duplications mentioned earlier, are
caused by the actions of the aforementioned mobile
(transposable) elements. Together, these elements
have acted dynamically to generate numerous, and
often substantial, chromosomal rearrangements,
which are the basis of many of the genetic differences between humans and chimpanzees, including gene gain and gene loss (33).
In 2005, Feuk and colleagues compared the
genomes of the two species and identified almost
1,600 inverted regions, which are equivalent to
approximately 5% of the human genome (39). They
noted that 151 of these inversions contained either
entire or partial genes, or a breakpoint that intersected a gene. Furthermore, they found 140 genes
with human-specific CNDs and 15 genes with
chimpanzee-specific CNDs, of which some were
important immunologically. A more-recent study
identified 252 inversion loci between human and
chimpanzee lineages, the junctions of which could
be easily characterised. Analysis of these junctions
directly implicated the aforementioned LINEs and
an abundant class of SINEs, known as Alu elements, in the inversion process (33). This study
also revealed a novel mechanism for some inversions that was responsible for 27 human-specific
events and for 22 chimpanzee-specific events.
These events affected exonic and intronic regions,
and had an impact on gene function via gene disruption, the generation of alternative splice sites,
and effects on gene regulatory regions. There are
approximately one million Alu elements in the
human genome with the power to effect these outcomes (40), and thereby greatly influence gene
expression (41).
Alu elements can also give rise to completely
new exons, often in existing functional genes, with
diverse splicing patterns (40). One such Aluderived exon has been implicated in a form of muscular dystrophy (42). More generally, Alu elements
have been associated with a number of diseases
that arise from disrupted gene function, including
various cancers, haemophilia, neurofibromatosis,
type-2 diabetes and Alzheimer’s disease (43).
Interestingly, the chimpanzee genome has 100,000
fewer Alu elements than the human genome, and
although 572 evolutionarily young Alu elements
have been identified in the human genome, just
160 such elements have been found in the chimpanzee genome (43). These great differences speak
once again to the inappropriateness of equating
research on chimpanzees to investigations based
on human subjects.
Large insertions and deletions of genetic material, or indels, are another source of significant
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variation between human and chimpanzee genomes. Volfovsky and colleagues compared twothirds of human chromosome 21 and its equivalent
in chimpanzees, chromosome 22 (there is an alternative chromosome nomenclature, in which
human and chimpanzee chromosomes are numbered similarly; based on this alternative nomenclature, the comparison involved human and
chimpanzee chromosome 22). This comparison
revealed 683 indels in the proximity of known
human genes, which potentially affected their
expression (44). Twenty-three of these indels were
within exons, or within splice-site regions, and ten
altered the sequence of the corresponding protein.
Indels have also been shown to affect major histocompatibility complex (MHC) genes, which are
critical for immune responses. Indeed, indels are
responsible for a large 95kb deletion in the MHC
locus that resulted in a virtual fusion of the MICA
and MICB human genes into the single hybrid
chimpanzee MIC gene (45). An additional 64 indels
of 100bp were identified in this locus, which is
genetically linked to differences in the handling of
various infections, including HIV, hepatitis B and
C viruses, and the malarial parasite, Plasmodium
falciparum, as well as susceptibility to autoimmune diseases.
Gene complement
Many genes are present in humans but entirely
absent in chimpanzees, or vice versa, largely due to
the duplication and deletion of large genomic
regions already noted. It has been reported that,
since the evolutionary split of humans and chimpanzees, humans have gained 689 genes and lost
86, while chimpanzees have gained 26 genes and
lost 729 that are still present in humans (46). This
means that humans differ by 6.4% in terms of their
gene complement alone (1,418 genes out of 22,000),
which has significant consequences. An example is
the golgin gene subfamily, which has been linked
to systemic autoimmune diseases such as lupus
erythematosus (47). In humans, this subfamily
comprises 49 genes, but only 23 genes in chimpanzees.
A comparison of protease genes, which encode
enzymes important in a wide variety of cellular
processes, showed that five genes had been completely deleted in the human genome, while the
corresponding number of deletions in the chimpanzee genome was just two (48, 49). Other studies have suggested: that 27% of human kinase
genes might not have a close homologue in chimpanzees (50); that 23% of human genes encoding
zinc-finger proteins, many of which modulate gene
transcription, might be absent in chimpanzees
(51); and that the presence of genes encoding cellsurface receptors of natural-killer cells, which are
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implicated in immunity to viral infection and surveillance for cancer, differs between the two
species (52).
Gene expression
Even in the majority of cases in which genes are
common to humans and chimpanzees, there are
substantial and widespread differences in their
expression. For example, a study examining the
expression of around 12,000 genes in the prefrontal cortex of the brain found that almost 1,000
were expressed in the human, but not in the chimpanzee, while the reverse occurred for 344 genes.
In addition, of the genes that were expressed in
both species, 20% showed a different expression
profile — for example, 19 genes linked to
Alzheimer’s, Parkinson’s and Huntington’s diseases in humans were found to be expressed differently in chimpanzees (53). In the cerebral
cortex, at least 169 genes are expressed differently
— many of which are involved in neuroprotection
and synaptic transport (54) — and 916 genes are
expressed at least two-fold differently in the cerebellum (55). Furthermore, many genes involved in
oxidative metabolism and mitochondrial function
are expressed to a higher degree in the human
brain than in the chimpanzee brain (56–58).
Not surprisingly, such differences are not confined to the brain. One study analysed an average
of approximately 10,500 genes in various human
and chimpanzee organs, and found that a striking
34% showed differential expression in the brain,
25% in the liver, 33% in the kidney, 35% in the
heart, and 62% in the testes (59). Another study,
which analysed even more genes (17,231), identified 16.3% of genes in the liver, 19.5% in the kidney, and 18.5% in the heart, that were expressed
at different levels within the two species (57).
These percentages amount to many thousands of
genes differentially expressed in various organs.
Notably, differences in the expression of a single
gene can have crucially important consequences:
the natural cytotoxicity receptor gene (NKp44), for
example, shows five-fold higher expression in
chimpanzees than in humans, and it exhibits differential increases upon activation. Its protein
product is involved in the recognition of HIV-1, and
in the sensing and killing of virus-infected and
cancerous cells. It is thought that these differences
could be at least partly responsible for the more
benign course of HIV infection in chimpanzees
(60).
It is highly likely that species variation in the
expression of just one gene, which encodes a member of the inhibitory sialic acid-recognising Igsuperfamily lectins (Siglecs), has a major effect on
comparative general immune responses to many
and varied pathogens. For example, Soto and co-
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workers (61) showed that inhibitory Siglecs generally, but in particular Siglec-5, are expressed at a
much lower level in humans than in chimpanzees.
The greater abundance of inhibitory Siglecs in
chimpanzees serves to dampen excessive immune
responses relative to humans, leaving human Tlymphocytes and B-lymphocytes, in comparison to
those of chimpanzees, over reactive to a variety of
stimuli. This may explain species differences in
diseases that involve immunopathology, including
HIV, hepatitis C, asthma, psoriasis and rheumatoid arthritis (61).
In addition, terminal sialic acids are produced in
larger amounts in the hearts of chimpanzees than
they are in those of humans (62). As these molecules are frequently the targets of viral pathogens
that can initiate fibrosis, their greater abundance
in chimpanzees makes myocardial fibrosis more
common in that species (63). Indeed, this type of
heart disease is the major cause of cardiac arrest
and progressive heart failure in chimpanzees, but
it is very different from the main cause of heart
disease in humans, which is coronary artery atherosclerosis (63). In common with the apparent
genetic factors underlying a greater incidence of
myocardial fibrosis in chimpanzees, it seems that
the increased incidence of atherosclerosis in
humans might also have a genetic cause — the
lack of Neu5Gc sialic acid (described further in the
Differences in Genetic Sequences section). A theory
is that humans ingest Neu5Gc sialic acid (as part
of their diet), and that this ‘foreign’ molecule triggers an immune response, causing inflammation
and exacerbating atherosclerosis. This chain of
events is augmented by the increased reactivity of
human T-cells caused by their lower expression of
inhibitory Siglecs, as noted above (61). In summary, it appears that a few differences in genetic
sequence and gene expression may be responsible
for very different pathologies of heart disease in
humans and chimpanzees (63).
Factors affecting gene expression
It is significant that many of the genes that are differentially expressed, often at a higher level in
humans, encode transcription factors, as these proteins can affect the regulation of many hundreds of
genes and can result in significant phenotypic
effects (64). Despite their understandably strict
evolutionary conservation, many transcription factors have evolved under directional selection in
humans (57, 65). A study by Nowick et al. illustrates this elegantly, as they identified 90 transcription factor genes with significantly different
expression levels in human and chimpanzee brains
(66). These gene networks were enriched for primate-specific KRAB-ZNF genes, which are central
to human and chimpanzee brains and are associ-
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ated with genes involved in the development and
maintenance of this organ.
Species differences in transcription factors create variations in gene expression, and thus generate physiological changes between humans and
chimpanzees. In addition, the role of transcription
factors in differential gene expression is augmented by variations in transcription factor binding sites between species. DNA sequence
variability at transcription factor binding sites is
normal between individuals of the same species:
for example, 25% of binding sites for RNA polymerase II vary between individual humans.
However, a statistically significant 32% of these
binding sites were found to have meaningful differences between humans and chimpanzees (67).
Differences in conserved non-coding sequences
flanking genes have been shown to have serious
implications for gene expression, as they may
affect three-quarters of human autosomal genes
(75.4% in one particular study; 68).
As an example of species-specific variability in
the influence of neighbouring non-coding regions, a
comparative analysis of 100 representative DNA
repair-associated genes in humans and chimpanzees revealed that 13% and 32%, respectively,
exhibited evidence of accelerated evolution in their
promoter and intronic regions (69). Some of those
genes also showed inter-species differences in
expression, which are thought to affect DNA repair
mechanisms. A faster rate of DNA repair in chimpanzee cells than in human cells, might contribute
to the different incidences of cancer between the
species.
Gene expression is also affected by DNA methylation patterns, which act epigenetically through
histone modification and chromatin remodelling to
mediate transcription (70). In common with all
alterations to cis-acting sequences, minor variations, or differences, in DNA methylation can
affect the expression of many genes. It has been
discovered that over 12% of methylation sites, covering one-third of all genes, might be differentially
methylated in humans and chimpanzees (71).
There are major differences in other factors that
control gene expression. For example, in recent
years microRNAs — small, 21–22 nucleotide RNA
molecules that can negatively regulate gene
expression by interfering with mRNA molecules,
either causing them to degrade or by blocking transcription — have received increasing attention (72,
73). There are thought to be over 1,000 miRNAs,
each of which can repress the expression of hundreds of genes in highly complex regulatory networks (74). They play crucial roles in cell
development, e.g. in signalling and differentiation,
and in cell fate, e.g. in apoptosis. As miRNAs regulate many oncogenes, perturbation of their function can induce the initiation and progression of
tumours (75). Interestingly, comparisons of human
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and chimpanzee precursor miRNAs have shown
that only 60% are identical, and that just 73%
show no change in their secondary structure (76).
In addition, around 10% of mature miRNAs are
different to some degree, and there are at least 39
miRNAs that are present in the human but not in
the chimpanzee (75). As a result of the fast evolution of miRNA binding sites (76), there are
undoubtedly species differences in the expression
levels of miRNAs (and in the selection and expression of target genes). At least 10% of miRNAs in
embryonic stem cells, which can differentiate into
over 200 different types of cell during development, differ between humans and chimpanzees
(77).
Adenosine-to-inosine RNA editing, another
important factor that affects gene expression, is
catalysed by an enzyme that post-transcriptionally
converts adenosine to inosine in RNA molecules,
resulting in RNA sequences in which inosines, in
place of the genomically-encoded adenosines, are
read as guanosine residues by the cell’s translational and splicing machinery. This process has
obvious consequences for any gene that is affected,
but importantly the process of editing is considerably more prominent in humans than in chimpanzees (78). In humans, it occurs predominantly
in the previously described Alu elements, and it
affects myriad loci across tens of thousands of
genes. When Alu elements in non-coding regions
are edited, gene expression can be altered; when
coding regions are edited, the amino acid
sequences, properties and functions of the encoded
proteins are changed. Because the brain is most
affected in this way, many of the targets of editing
are associated with the genes involved in neurogenesis. Altered editing is therefore associated with a
number of neuropathological disorders. The differential editing between humans and chimpanzees
has distinct effects on gene expression and function via alternative splicing and differences in
mRNA stability, nuclear retention and miRNA biogenesis and targeting (78).
Differences in genetic sequences
In addition to the large-scale genomic rearrangements, such as inversions, indels, duplications,
and so forth already discussed, as well as the disparities in gene complement, there are smaller
apparent differences that can have a considerable
impact on human and chimpanzee physiology and
that are responsible for notable inter-species differences.
A recent analysis of chimpanzee genes ‘equivalent’ to 333 human genes implicated in cancer (79)
found that the genes shared a high degree of similarity. This would be expected, because genes controlling cell growth are often tightly conserved
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throughout evolution. However, 20 of the 333
genes, some of which are definitively involved in
tumour formation, had some level of difference.
This may help to explain why chimpanzees have
an extraordinarily low incidence of cancers, especially those of the breast, prostate and lung, cancers that account for over 20% of human deaths in
modern populations (12). Another analysis, this
one of human and chimpanzee protease genes
(which are involved in many essential biological
processes), revealed important differences: a high
degree of similarity was discovered between the
559 chimpanzee and 561 human protease genes,
but seven genes were deleted entirely (i.e. two
genes present in chimpanzees were absent in
humans, and the opposite was true for five genes;
48). Many other genes contained small insertions,
deletions or sequence changes that can lead to
gene inactivation, and several of these genes were
involved in the function of the immune system
(48).
Another study identified 54 genes in humans
and 162 genes in chimpanzees that had undergone
positive selection since the evolutionary split
between the species. Just 17 genes had been positively selected in both species (80). Notably, the
genes positively selected in humans have been
implicated in epithelial cancers, schizophrenia and
other cognitive disorders, ataxia and migraine,
autoimmune diseases such as lupus and rheumatoid arthritis, and Alzheimer’s disease, all of which
differ in prevalence and symptoms between
humans and chimpanzees (80). The positively
selected genes included those involved in: DNA
repair, general tumour progression, gastric and
breast cancers, susceptibility to and progression of
melanoma, neurological development, various
ataxias, migraine, dystonia, epilepsy, bipolar disorder and cognitive impairment. Differences in
transcription factor genes were also found, including the HIVEP3 gene, which activates gene expression in HIV and which may account for some of the
species differences in HIV/AIDS, and other genes
involved in regulating gene expression such as
MOV10, which is involved in the silencing of
mRNA molecules.
Although Volfovsky et al. (44), in the study previously reported, identified 683 large indels
between chimpanzee chromosome 22 and its
human counterpart chromosome 21, an earlier,
more-detailed analysis of these chromosomes
revealed a total of around 68,000 indels of all sizes,
resulting in genetic differences in the 231 genes
therein, leading to differences between humans
and chimpanzees in 83% of the protein products
(81). In addition, around 1 in 10 of these genes
showed significant differences in their expression
levels. Another study found that about 8%
(1,109/13,487) of the human/chimpanzee gene
pairs analysed were affected by premature stop
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codons in the chimpanzee version, resulting in
truncated mRNA transcriptional products that are
either degraded, or that give rise to truncated proteins with altered or ablated functions (17).
Elsewhere, an analysis of all human and chimpanzee exons showed that humans have 1,931 disrupted exons (there are more than 500,000 in
total), while the chimpanzee has 3,742 disrupted
exons (82). In humans, functional consequences of
these disruptions identified to date include
melanoma, breast cancer, neuroblastoma, some
inflammatory diseases, problems of immune and
cardiovascular development, lupus and stress
responses.
Specific examples of small genetic changes with
major, or at least potentially major, consequences
are commonplace. For example, the CMP-sialic
acid hydroxylase gene in humans contains a small
deletion of a 92bp exon that is not found in the
chimpanzee gene. This deletion causes a frameshift that results in loss of function of the protein.
Deficiency of this enzyme activity means that
humans, unlike chimpanzees, do not have a particular sialic acid residue (N-glycolyl-neuraminic
acid, or Neu5Gc) on the surface of almost all of the
cells in their bodies. The absence of this residue
has implications for intercellular interactions and
many other biological processes, as well as for susceptibility (and resistance) to microbial pathogens
(83). The CDR4 gene, which encodes the CDR4 cell
receptor that is a major part of the receptor complex for HIV and thus its route of infection of
immune cells, differs between humans and chimpanzees significantly. This difference affects CDR4
regulation, expression, density on the cell surface
and glycosylation — factors that influence its
structure, stability, and ability to interact with
other immune cells. These small genetic differences between humans and chimpanzees therefore
have serious consequences for HIV infection and
pathology, and underlie some of the differences
seen in HIV/AIDS between the species (84).
The differences in the genomic complement of
protease genes (48), which were discussed earlier,
may be significant, despite the overall similarity of
the human and chimpanzee degradomes and their
constituent genes. Important differences also exist
in protease genes that are common to the two
species, particularly in those genes related to host
defence, such as neutrophil granule proteases and
processors of pro-inflammatory cytokines (49).
These differences are notable, because of the wide
variety of critical functions in which the enzymes
are involved, such as: cell cycle progression; cellular proliferation, differentiation and migration;
embryonic development; tissue remodelling; angiogenesis; apoptosis, autophagy and senescence; fertilisation; immunity; wound healing; and
haemostasis (49). The importance of proteases, and
of the effects of their differential regulation or
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mutation, is further reflected in the array of
human diseases with which they are associated,
including: cancer, arthritis, neurodegenerative and
cardiovascular disorders, haemophilia, Alzheimer’s
disease, hereditary pancreatitis, and progeroid
syndromes (49).
A deletion of two base pairs in the human
MYH16 gene resulted in a frameshift that reduced
the sizes of jaw muscles in humans and allowed a
larger brain to develop (85). A single base pair substitution caused an inactivating, premature stop
codon in the human type I hair keratin gene, which
resulted in smooth, hairless skin in humans, in
contrast to the very hairy skin of chimpanzees (86).
Sequence differences in the FOXP2 gene, resulting
in just two amino acids that are different in the
protein product, have been linked with a species
difference of almost immeasurable magnitude and
consequence — the acquisition of human language
(87).
While inter-species sequence disparities for any
particular gene may have obvious direct consequences due to the potential variability of that
gene’s protein products and their immediate functional activities, it must also be appreciated that
indirect effects may be significant as well. The
aforementioned FOXP2 gene, for example, in addition to its own structural and functional differences between humans and chimpanzees,
differentially and significantly affects the expression of a further 116 genes. In humans, but not in
chimpanzees, 61 genes are up-regulated and
another 55 are down-regulated by the FOXP2 protein (88). The genes involved are important for
brain development and function (for example,
those involved in craniofacial formation and in
establishing the neural circuitry and physical
structures needed for spoken language via cerebellar motor function), and in the formation of cartilage and connective tissue.
Differences in RNA splicing
Splicing factors are complexes of proteins and RNA
that bind to specific sequences in pre-mRNA intermediates during transcription, and splice out
intronic sequences to generate multiple mRNA
molecules from one gene. Their presence, nature,
function and repertoire, therefore have far-reaching consequences for the expression of many other
genes. They greatly increase the complexity of the
genome and proteome, and over 80% of human
genes are subject to their action (89). It is critical
to note that many splicing factors are differentially
expressed in humans and chimpanzees; for example, 43 in the testes and 20 in the brain (90). This
alone will result in many protein variants, which
may have distinct functions in the tissues and
organs of humans and chimpanzees. As previously
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described, the inter-species consequences of differential alternative splicing are further amplified by
the differential action of mobile elements and
adenosine-inosine RNA editing in generating and
deleting alternative splice sites (33, 40, 44, 78).
Post-translational differences
The genomic and transcriptomic differences
described earlier obviously translate into proteomic differences, with consequent inter-species
diversity in protein function, biochemistry and
physiology. In addition, there are comparative proteomic studies that directly inform our knowledge
of human/chimpanzee differences at the protein
level. For example, 80% of orthologous proteins
were found to differ in their amino acid sequences
(91) by an average of two amino acids per protein
(92), which has clear implications for evaluating
the applicability of data from chimpanzees.
Furthermore, a comparative analysis of proteins
that interact with HIV-1 revealed that, of 1,447
such human proteins, 77 had no orthologue in nonhumans, including chimpanzees (93). The same
study revealed significant differences between
humans and chimpanzees in the group of
APOBEC3 proteins, which are involved in host
defence against retroviruses. Of the 1,370 human
and chimpanzee orthologous proteins that were
compared, each species had more than 600 speciesspecific phosphorylation sites, potentially affecting
thousands of protein–protein interactions, enzyme
activities and protein stabilities (93).
The consequences of genetic differences:
Evaluation of the translation of data from
chimpanzee research to humans
Several critical analyses have reflected serious
concerns about the human relevance of chimpanzee research and the capacity of chimpanzee
data to produce tangible clinical benefits. While
each of these representative studies set out with
the hypothesis that chimpanzee experimentation
was not a productive, or necessary, research
methodology, their conclusions are supported by
substantial data. Furthermore, it must be noted
that each study provides numerous peer-reviewed
publications, as well as professional opinion and
comment to substantiate its conclusions. Caveats
surrounding the efficacy of chimpanzee research
are indeed widespread, and they emanate from
many and varied qualified sources.
In 2007, a citation analysis by Knight (13) and
Bailey and colleagues (see http://www.release
chimps.org/pdfs/chimp-efficacy-paper-main.pdf
and http://www.releasechimps.org/pdfs/Chimp-CAsuppl.pdf) provided a general overview of the per-
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ceived and actual importance of chimpanzee
research, amid claims from its advocates that it is
crucial and takes place only when absolutely necessary (as expressed, for example, by VandeBerg
and Zola [4]). If these claims were actually wellfounded, papers reporting chimpanzee research
should be heavily cited in the literature describing
advances in human medicine, but the 2007 analysis found this not to be the case. By using a statistically representative sample of almost 100
published papers, the analysis revealed that more
than 85% of the chimpanzee studies had not been
cited at all in papers relevant to human medicine.
Furthermore, a thorough and detailed analysis of
the papers cited in a human medical context, and
of those that had cited them, revealed that the
chimpanzee studies had contributed little, if anything, to the outcome of the human studies. Often,
the results from research involving chimpanzees
were duplications of human outcomes that had
already been reported in earlier papers, or the conclusions were inconsistent with data on humans or
other non-human primates. In contrast, the analysis found it demonstrable that in vitro research,
human clinical and epidemiological investigations,
and molecular and genomic methods had contributed most to the findings of the 95 papers in
the sample.
A review that examined the use of chimpanzees
in HIV/AIDS research (11) found that the number
of AIDS-related chimpanzee studies fell by nearly
90% between 1998 and 2005, apparently because of
the poor clinical translation of, and need for, that
line of research. Responses to HIV vaccines were
highly discordant in humans and chimpanzees, so
the review concluded that responses to vaccination
in chimpanzees could not be considered predictive
of responses in humans. In fact, according to the
same review, 85 diverse HIV vaccines that were
developed by using chimpanzees and other primates and shown to have protective, or therapeutic effects, were evaluated in 197 human clinical
trials. Yet, protection and/or significant therapeutic effects in humans have still not been demonstrated by any HIV vaccine, despite decades of
effort and many millions of dollars of research
funding. Thus, contrary to claims that chimpanzees “are still important for testing vaccines
aimed at preventing HIV-1 infection or reducing
the virus load in infected individuals”, for example
(4), it was concluded that neither claim has any scientific foundation, and that a return to the use of
chimpanzees in AIDS research/vaccine development would be without scientific justification.
Chimpanzees have scarcely been used in any
form of cancer research, which may be surprising
when one considers that cancer is one of the greatest killers of human beings. A review of the subject
showed that there have been very few scientific
publications relevant to human cancer that used
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chimpanzees, and that tumours in chimpanzees
are extremely rare, especially of the types that are
responsible for most of the deaths from cancer
among humans (12). The review found that chimpanzee tumours are biologically different from
those of humans, and this includes the tumour initiation and progression phases. These observations
demonstrate that, despite their overall apparent
genetic similarity to humans, chimpanzees constitute a poor research model for human cancer.
Furthermore, these animals are not essential for
the development of therapeutic monoclonal antibodies for cancer treatment. Finally, the review
found that published papers describing potential
new cancer therapies tested in chimpanzees often
included significant caveats concerning differences
in the species, acknowledged that research with
chimpanzees was no better than research with
other animals, and described interventions that
had not been pursued clinically, presumably due to
adverse preclinical results (12). These conclusions
are supported by many of the genetic differences
between humans and chimpanzees described in
the present paper.
Finally, two in-depth reviews by the author of
the present paper have recently been completed.
These address claims that research with chimpanzees must continue in order to provide a better
understanding of hepatitis C, and to realise treatments and cures for this devastating disease that
affects millions of people worldwide (9, 10). This is
important, not only due to the impact of hepatitis
C on the human population, but also because it
represents the area of greatest use of chimpanzees
in laboratories at present. These two reviews
demonstrate that researchers have, for many
years, cited numerous serious caveats and problems with the chimpanzee model. They have also
stressed the urgent need for in vitro viral culture
systems to accelerate progress, which occurred
much earlier for other viruses, such as polio and
measles. Paralleling the case of HIV/AIDS, these
caveats, and the need for in vitro culture systems,
are due to major pathological differences between
human and chimpanzee hepatitis C virus infection.
The reviews show that in vitro and clinical
approaches, rather than chimpanzee experiments,
have provided the most substantial, comprehensive and important data. It is now possible to
investigate the entire life cycle of the hepatitis C
virus, immune responses and host factors, identify
therapeutic targets, and test new therapies and
vaccines, in a human, and therefore completely relevant, context. The reviews show that chimpanzee
use is declining markedly in research on hepatitis
C; indeed, it has fallen by over 60% in the last 20
years and is now at a historical low of just onethird of its 1985 peak level. In contrast, non-animal research on hepatitis C has increased 80-fold
over the same time period. In summary, in the
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area of hepatitis C research, the arguments are
strongly against a scientifically based requirement
for the use of chimpanzees and very much in
favour of concentrating research in human-specific
clinical and in vitro technologies.

Discussion and Conclusions
The conduct of invasive research on captive chimpanzees may never have been more controversial
than it is today. In recent years, experimentation on
chimpanzees has been outlawed, or at least severely
restricted, in the relatively few scientifically
advanced nations where it was ever practised (see
http://www.releasechimps.org/mission/end-chimpanzee-research/country-bans/). Nevertheless, some
observers still insist that such restriction is a mistake (4). Legislation banning experimentation on
chimpanzees has been implemented largely due to
ethical concerns — namely, that research with
chimpanzees causes extreme pain and suffering to
animals with very highly developed cognitive and
emotional capacities. This rationale is being
increasingly augmented by a burgeoning scientific
argument — that data from chimpanzee experiments are flawed and invalid with regard to human
medicine, and that superior alternatives, with
greater human relevance, do exist. This argument,
in turn, is bolstered by our increasing knowledge of
the genetic differences between humans and chimpanzees, as was summarised in this review, which
serve to explain the negative results and conclusions reached in critical assessments of the relevance of the chimpanzee for many areas of research
on human disease. These negative results and conclusions, briefly summarised above, also give value
and meaning to those genetic differences, showing
that they do indeed matter and that they combine to
make the chimpanzee a very different species from
the human.
Yet, in spite of this substantial and compelling
knowledge, the ostensibly extreme genetic similarity of chimpanzees and humans is frequently used
to assert the validity and indispensability of chimpanzee research. An example from 2005 is a highprofile opinion piece by two prominent chimpanzee
researchers, from two institutions housing hundreds of research chimpanzees, in which they
make a plea for increased research on captive
chimpanzees (4). It is conceded that the chimpanzee is the species most genetically similar to
humans, although the complexity of aligning such
huge genomes makes it difficult, if not impossible,
to measure this similarity in a truly precise way.
Initial estimates suggested this similarity was
around 98.5% to 99% (King and Wilson [94],
reviewed by Varki [95]), a figure that has been confirmed more recently, although with certain
caveats (reviewed by Volfovsky et al. [44],
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Watanabe et al. [81], and the Chimpanzee
Sequencing and Analysis Consortium [92], among
others). For instance, the figure of 98.5–99% takes
into account nucleotide substitutions only. When
genomic insertions and deletions are considered,
the overall similarity decreases to approximately
95–96% (14, 15), or to as low as 93.5% (16). Even
when repeat-sequence and low-complexity DNA
are excluded, the overall difference is still thought
to be approaching 2.5%, which is double the original and highly cited estimate (16).
It has been widely acknowledged for some years
that a genetic difference of only 1–2% is actually a
‘myth’, but its fragile underpinnings have apparently been overlooked by advocates of chimpanzee
research in their defence of the practice. Their
assertion of a high genetic similarity and of only a
1–2% difference is even more surprising when one
appreciates the extent of the awareness within the
scientific community of other important interspecies disparities and their phenotypic effects,
and for how long this awareness has existed. As
long ago as 1975, the authors of a seminal study
(94) that indicated a 1% difference between
humans and chimpanzees insisted that ‘‘the
genetic distance between humans and the chimpanzee is probably too small to account for their
substantial organismal differences’’. In other
words, differences in gene regulation and expression, rather than protein-coding mutations, must
play a major role (46, 94, 96). Knowledge of other
factors with a great influence on gene expression
and human/chimpanzee phenotypes also precedes
and surrounds such claims. As this review demonstrates, various phenomena — including genomic
rearrangements, mobile DNA elements (e.g.
LINEs and SINEs), gene duplications and deletions, copy number variation, differences in transcription factors and binding sites, DNA
methylation, miRNAs and binding sites, gene editing and splicing and protein phosphorylation —
contribute to human/chimpanzee biological differences. Many of these factors affect gene expression
and function, and are deemed to have played a
greater role than simple nucleotide substitutions
in the evolution of species-specific phenotypes. As
opined in a review outlining significant gene gain
and loss in humans and chimpanzees: “Without
accounting for differences in the total DNA unique
to each species, we cannot hope to take a proper
accounting of the meaningful genetic divergence
between humans and chimpanzees” (46).
As the recent analyses summarised in this
review show, the divergence between humans and
chimpanzees is considerable, and it translates to
major differences in susceptibility to disease, in
symptoms and in pathologies. These differences
have “eluded any molecular explanation within
this supposedly 1% diversity range” (45), a diversity which “is clearly misleading” (91). Humans,
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for example, are more susceptible to a variety of
“infectious diseases, cardiovascular diseases, obesity, type II diabetes, autoimmune diseases, major
psychoses, and neurodegenerative diseases” (69),
are more prone to developing cancer (12, 59), and
are differently susceptible to malarial parasites
when they are compared to chimpanzees (97).
Experimentation with chimpanzees has failed to
translate to meaningful progress in HIV/AIDS
(11), hepatitis C (9, 10) and cancer (12), as well as
more generally for other diseases (13; see also
http://www.releasechimps.org/pdfs/chimp-efficacypaper-main.pdf and http://www.releasechimps.
org/pdfs/Chimp-CA-suppl.pdf).
The use of chimpanzees has declined greatly in
all areas of research, and it cannot be shown to be
necessary in any current field of biomedical
research. It has been falsely credited with major
breakthroughs in the past, where human-specific
methods were the true contributors, while modern
technologies and cutting-edge alternative methods
negate any value it may have had historically. The
presumed benefits are arguable in themselves. It
must therefore be concluded that any justification
of chimpanzee research based on genetic similarity
is superficial and incorrect. And, based on a deeper
and more thorough appreciation of profound interspecies differences in gene expression, rather than
simple genetic similarity, it must be concluded
that the chimpanzee does not, and can never, constitute a crucial and indispensable model for
human biomedical research.
When the scientific case against chimpanzee
experimentation is considered alongside the
numerous and varied concerns about animal welfare, ethical issues and financial concerns (7, 8),
the argument becomes even more compelling and
formidable. Studies have revealed post-traumatic
stress disorder in ex-research chimpanzees now in
sanctuary (5, 98), and have detailed physical and
psychological trauma suffered by chimpanzees
that have been raised in various human/chimpanzee contexts and then used in research, as well
as the chimpanzees’ ability to recover from such
trauma once in sanctuary (6). Tens of millions of
taxpayer dollars could be saved each year by transferring all federally owned and supported chimpanzees from laboratories to sanctuaries, where
they would receive superior care and enjoy a
higher quality of life (Capaldo and Owens, submitted). Public opinion polls show that twice as many
Americans support a ban on chimpanzee research
as oppose one, and that 71% of the American public think chimpanzees used in research for more
than 10 years should be retired (this figure would
now include over 90% of all chimpanzees in US laboratories; see http://www.releasechimps.org/mission/end-chimpanzee-research/public-opinion/).
Finally, chimpanzee experimentation is a ‘special
case’. This is evidenced not only by public opinion,
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but also by various policies and laws in the USA,
such as: the CHIMP Act passed in 2000 (99); the
extension, in 2007, of a moratorium in place since
1995 on breeding chimpanzees which applies to
federally supported chimpanzees in US laboratories (see http://www.releasechimps.org/2007/05/
22/breeding-moratorium-decision-good-news/); the
many countries that have recently banned or
severely limited the use of great apes (see http://
www.releasechimps.org/mission/end-chimpanzeeresearch/country-bans/); and the considerable legislative support in both the US House of
Representatives and the US Senate for GAPCSA
(the Great Ape Protection and Cost Savings Act),
which seeks to end invasive chimpanzee research
and retire all federally owned chimpanzees in US
laboratories to permanent sanctuary (23, 24).
To the best available knowledge, the USA is the
only country in the world that actively conducts
invasive research on captive chimpanzees to any
significant degree. For the sake of the approximately 1,000 chimpanzees in US laboratories, who
almost without exception are elderly and have suffered greatly, there is a strong argument for the
USA to join the rest of the world and end this
research. There is also a strong argument to end
this research for the sake of humanity, which
stands to benefit from superior, more humane, and
more human-relevant scientific inquiry, should the
use of chimpanzees cease. The evidence reviewed
here shows that chimpanzees are simply not
‘human enough’ to constitute valuable models for
research on human diseases: important differences, with serious biological consequences, run
right through each level of gene expression and
protein function, from chromosome and chromatin
structure to post-translational modification. This
results in non-predictive data of poor relevance to
humans, that rarely translate to the clinic and that
actually impede progress in human medicine. The
argument that chimpanzees must constitute a
good model for research on human diseases, based
on their ostensible genetic similarity to humans, is
specious and should be dismissed. Only by moving
away from chimpanzee research, and by fully
embracing and adopting superior human-specific
alternatives, can treatments or cures for the many
diseases that blight the lives of hundreds of millions of people be realised quickly and safely.
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